146 related articles for article (PubMed ID: 14565246)
81. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
82. Diversity of DNA topoisomerases I and inhibitors.
Pommier Y
Biochimie; 1998 Mar; 80(3):255-70. PubMed ID: 9615865
[TBL] [Abstract][Full Text] [Related]
83. Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.
Fowler JD; Brown JA; Johnson KA; Suo Z
J Biol Chem; 2008 May; 283(22):15339-48. PubMed ID: 18378680
[TBL] [Abstract][Full Text] [Related]
84. Synergistic interaction between cisplatin and gemcitabine in vitro.
Bergman AM; Ruiz van Haperen VW; Veerman G; Kuiper CM; Peters GJ
Clin Cancer Res; 1996 Mar; 2(3):521-30. PubMed ID: 9816199
[TBL] [Abstract][Full Text] [Related]
85. In vitro assessment of nucleoside analogs in multiple myeloma.
Krett NL; Ayres M; Nabhan C; Ma C; Nowak B; Nawrocki S; Rosen ST; Gandhi V
Cancer Chemother Pharmacol; 2004 Aug; 54(2):113-21. PubMed ID: 15133625
[TBL] [Abstract][Full Text] [Related]
86. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Yang LY; Li L; Jiang H; Shen Y; Plunkett W
Clin Cancer Res; 2000 Mar; 6(3):773-81. PubMed ID: 10741696
[TBL] [Abstract][Full Text] [Related]
87. Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme.
Van Rompay AR; Johansson M; Karlsson A
Mol Pharmacol; 1999 Sep; 56(3):562-9. PubMed ID: 10462544
[TBL] [Abstract][Full Text] [Related]
88. Topoisomerase I-mediated cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine: trapping of topoisomerase I by the O6-methylguanine.
Pourquier P; Waltman JL; Urasaki Y; Loktionova NA; Pegg AE; Nitiss JL; Pommier Y
Cancer Res; 2001 Jan; 61(1):53-8. PubMed ID: 11196197
[TBL] [Abstract][Full Text] [Related]
89. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides.
Obata T; Endo Y; Tanaka M; Uchida H; Matsuda A; Sasaki T
Jpn J Cancer Res; 2001 Jul; 92(7):793-8. PubMed ID: 11473731
[TBL] [Abstract][Full Text] [Related]
90. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin.
Desai SD; Liu LF; Vazquez-Abad D; D'Arpa P
J Biol Chem; 1997 Sep; 272(39):24159-64. PubMed ID: 9305865
[TBL] [Abstract][Full Text] [Related]
91. Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2'-deoxyguanosine.
Antony S; Theruvathu JA; Brooks PJ; Lesher DT; Redinbo M; Pommier Y
Nucleic Acids Res; 2004; 32(18):5685-92. PubMed ID: 15498925
[TBL] [Abstract][Full Text] [Related]
92. Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
Heinemann V; Xu YZ; Chubb S; Sen A; Hertel LW; Grindey GB; Plunkett W
Cancer Res; 1992 Feb; 52(3):533-9. PubMed ID: 1732039
[TBL] [Abstract][Full Text] [Related]
93. Human topoisomerase I inhibition: docking camptothecin and derivatives into a structure-based active site model.
Laco GS; Collins JR; Luke BT; Kroth H; Sayer JM; Jerina DM; Pommier Y
Biochemistry; 2002 Feb; 41(5):1428-35. PubMed ID: 11814334
[TBL] [Abstract][Full Text] [Related]
94. Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Hubeek I; Peters GJ; Broekhuizen AJ; Kaspers GJ
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1513-6. PubMed ID: 15571288
[TBL] [Abstract][Full Text] [Related]
95. The expression and activity of thymidine kinase 1 and deoxycytidine kinase are modulated by hydrogen peroxide and nucleoside analogs.
Sun R; Eriksson S; Wang L
Nucleosides Nucleotides Nucleic Acids; 2020; 39(10-12):1347-1358. PubMed ID: 32189555
[TBL] [Abstract][Full Text] [Related]
96. Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.
van Bree C; Rodermond H; Leen R; Medema J; van Kuilenburg A
Br J Cancer; 2008 Apr; 98(7):1226-33. PubMed ID: 18349845
[TBL] [Abstract][Full Text] [Related]
97. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells.
Sarkar M; Han T; Damaraju V; Carpenter P; Cass CE; Agarwal RP
Biochem Pharmacol; 2005 Aug; 70(3):426-32. PubMed ID: 15950950
[TBL] [Abstract][Full Text] [Related]
98. Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Cartei G; Trestin A; Colombrino E; Nadai M; Richter SN; Barzon L; Palù G; Palumbo M;
Ann Oncol; 2006 May; 17 Suppl 5():v25-28. PubMed ID: 16807458
[TBL] [Abstract][Full Text] [Related]
99. Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Braess J; Wegendt C; Jahns-Streubel G; Kern W; Keye S; Unterhalt M; Schleyer E; Hiddemann W
Br J Haematol; 2000 May; 109(2):388-95. PubMed ID: 10848830
[TBL] [Abstract][Full Text] [Related]
100. Differential induction of topoisomerase I-DNA cleavage complexes by the indenoisoquinoline MJ-III-65 (NSC 706744) and camptothecin: base sequence analysis and activity against camptothecin-resistant topoisomerases I.
Antony S; Jayaraman M; Laco G; Kohlhagen G; Kohn KW; Cushman M; Pommier Y
Cancer Res; 2003 Nov; 63(21):7428-35. PubMed ID: 14612542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
